other Related Fields Related Fields کنگره Congress <div style="text-align: justify;"><span style="font-family:Times New Roman;"><span style="font-size:11pt"><span style="line-height:normal"><span style="unicode-bidi:embed"><b><span style="font-size:10.5pt">Introduction: </span></b><span style="font-size:10.5pt">Plasma medicine, an emerging field at the intersection of plasma physics, chemistry, and life sciences, offers novel therapeutic pathways for wound healing, sterilization, cancer treatment, and tissue regeneration. Despite promising outcomes in preclinical studies, its clinical translation remains constrained by limited safety validation and the lack of harmonized international standards and policy frameworks. This study aimed to analyze current safety and regulatory challenges within plasma medicine, identify deficiencies in existing standards, and propose foundational requirements for developing evidence-based policies.</span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="unicode-bidi:embed"><b><span style="font-size:10.5pt">Materials and Methods: </span></b><span style="font-size:10.5pt">We conducted a comprehensive review of regulatory and technical documents (ISO, IEC, FDA, and EMA). We also analyzed peer-reviewed studies on plasma-tissue interactions, device characterization, and risk assessment. A Comparative evaluation of plasma source parameters, reactive species dynamics, and biocompatibility data was performed to highlight key safety domains and inform policy recommendations.</span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="unicode-bidi:embed"><b><span style="font-size:10.5pt">Results and Discussion: </span></b><span style="font-size:10.5pt">Our findings reveal a fragmented regulatory landscape characterized by inconsistent terminology, absence of standardized dosimetry models, and insufficient long-term cytogenetic safety data. Major risk areas include uncontrolled exposure to reactive species, thermal and electrical effects, and variability in biological responses. We recommend the establishment of validated reference devices, standardized testing protocols, and harmonized safety thresholds as prerequisites for coherent policymaking.<span style="font-family:"Calibri",sans-serif"></span></span></span></span></span><br> <b><span style="font-size:10.5pt"><span style="line-height:107%">Conclusion: </span></span></b><span style="font-size:10.5pt"><span style="line-height:107%">The safe integration of plasma-based technologies into healthcare systems requires interdisciplinary coordination among researchers, clinicians, manufacturers, and regulatory bodies. Development of internationally recognized standards, grounded in reproducible safety metrics and transparent evaluation procedures, is essential for advancing plasma medicine from experimental research to regulated clinical practice.</span></span></span></div> <br> &nbsp; <table align="center" border="1" cellpadding="0" cellspacing="0"> <tbody> <tr> <td></td> <td><img alt="" height="84" src="./files/site1/images/Picture1.jpg" width="507" ></td> <td></td> </tr> </tbody> </table> Health policy, Medical device safety, Plasma medicine, Regulatory standards plasma-tissue interaction, Risk management 8 8 http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-870&slc_lang=other&sid=1 Farzaneh Moradi Yes